AI-powered search

What Factors Predict Super-Response to Guselkumab in Psoriasis?

Patient age, baseline body weight, disease severity measured by PASI, Investigator's Global Assessment predict response to guselkumab

By Dermsquared Editorial Team | December 07, 2022

Guselkumab is more likely to be associated with achieving super-response among patients who are younger, less obese, and have less severe psoriasis, according to a study published in the December issue of the Journal of the European Academy of Dermatology and Venereology.

Kristian Reich, M.D., from the University Medical Center Hamburg-Eppendorf in Germany, and colleagues describe the baseline characteristics of patients with moderate-to-severe psoriasis achieving super-response (Psoriasis Area and Severity Index [PASI] 100 response at weeks 20 and 28) after initiating guselkumab treatment using pooled data from the VOYAGE 1 and VOYAGE 2 studies. Factors that were potentially predictive of super-response status were identified.

The post-hoc analysis included 664 patients: 271 achieved super-response and 393 had a non-super-response. The researchers found that significant predictors of super-response status included patient age at study entry, baseline body weight (≤90 versus >90 kg), PASI, and the Investigator's Global Assessment score. Compared with those with non-super-response, more patients with super-response achieved an early response (week 2 PASI 75: 5.5 versus 1.8 percent; week 8 PASI 100: 22.5 versus 3.3 percent). Patients with versus without super-response had slightly greater median serum guselkumab concentrations through week 28.

"Guselkumab-treated patients with super-response have distinguishable baseline demographic and disease characteristics," the authors write. "These results may allow clinicians to predict which patients at their baseline might achieve super-response, which may be beneficial in drug selection, managing patient expectations of treatment response, and improving patient-physician communication."

Several authors disclosed financial ties to pharmaceutical companies, including Janssen, which manufactures guselkumab and partially funded the study.


The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved